Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Ottignies-Louvain-La-Neuve – page 150

1 888 clinical trials in Ottignies-Louvain-La-Neuve, Belgium across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Ottignies-Louvain-La-Neuve at a glance
1 888
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 888 trials in Ottignies-Louvain-La-Neuve

Open in trial search

Myelofibrosis+2

Not recruiting

Continued Treatment Study for Patients with Myelofibrosis, Post-Lung Transplant BOS, or Chronic Graft-Versus-Host Disease Using Itacitinib

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Itacitinib
  • Sponsor:Incyte Corp.

Dermatomyositis

Not recruiting

Study on the Effects of GLPG3667 for Adults with Dermatomyositis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:GLPG3667 fumarate
  • Sponsor:Lakefront Biotherapeutics

Study of Capivasertib with CDK4/6 Inhibitors and Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:AstraZeneca AB

Colitis ulcerative

Not recruiting

Study on the Effects of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Obefazimod
  • Sponsor:Abivax

Hidradenitis

Not recruiting

Study to Evaluate the Effectiveness of Spesolimab for Patients with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Spesolimab
  • Sponsor:Boehringer Ingelheim Espana S.A.

Portal hypertension

Not recruiting

Study on BI 685509 and Empagliflozin for Patients with Portal Hypertension in Compensated Cirrhosis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:BI 685509
  • Sponsor:Boehringer Ingelheim Espana S.A.

Hyperoxaluria

Not recruiting

Study on Lumasiran for Patients with Advanced Primary Hyperoxaluria Type 1

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Lumasiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

Long-Term Follow-Up Study of Imlifidase in Highly Sensitized Kidney Transplant Patients

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Imlifidase
  • Sponsor:Hansa Biopharma AB

Study on the Effects of MK-5475 for Adults with Pulmonary Arterial Hypertension

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Frespaciguat
  • Sponsor:Merck Sharp & Dohme LLC

Study Comparing DZD9008 and Chemotherapy for First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Mutation

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Dizal Pharmaceutical Co. Ltd.

Obesity+1

Not recruiting

Study on the Effects of Semaglutide for Weight Management in Children and Adolescents with Obesity or Overweight

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Endometrial cancer+4

Not recruiting

Study on the Safety and Effectiveness of SKB264 and Pembrolizumab for Patients with Cervical, Urothelial, Ovarian, or Prostate Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Anhydrous Caffeine
  • Sponsor:Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Ottignies-Louvain-La-Neuve

What the registry says about research in the country

01 Hematology & Oncology Research

Groundbreaking clinical trials focusing on multiple myeloma treatments, specifically targeting patients with relapsed or refractory conditions. The research evaluates innovative combination therapies including talquetamab and daratumumab administration.

  • Blood Cancer Therapeutics
  • Novel Drug Combinations
  • Treatment Resistance

This comparative study aims to advance treatment options for patients who have undergone at least one prior line of therapy, potentially offering new hope for those with difficult-to-treat blood cancers.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.